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Current nucleotide or nucleoside analogs have been
commonly applied to treat chronic hepatitis B patients.
These drugs effectively block de novo HBV DNA synthesis
and almost suppress HBV replication. It always achieves
a depletion of HBV virions from the blood stream of
the patients. However, it could not eradicate HBV DNA,
especially the ccc DNA, in the hepatocytes already infected
by HBV. The intrahepatic HBV cccDNA continue active
transcription and reverse transcription, an error-prone
process to generate large population of HBV variants. A tiny
proportion of these HBV variants may acquire the ability to
escape the suppression of nucleot(s)ide analogs, because of
their genetic changes. These genetic changes may confer
the ability of variant HBV able to start replication, even
in the presence of anti-viral NAs. Despite of this new
capacity, such variants usually replicate poorly, unless they
acquire new mutations which compensate the replication
activity (so-called compensatory mutations, or secondary
mutations). Therefore it is important to distinguish between
genotypic resistance to vriological resistance towards anti-
viral NAs. The sequences variants in the HBV genomes render
viruses able to replicate (even minimally) in the anti-viral
NAs are named genotypic resistance. However, many of
these mutants are not potent enough to support active HBV
variant replication, so few HBV are released and detected.
Until there are other new genotypic mutations take place
and make the replication level sufﬁcient high, then the HBV
variants become prominent in the circulation and result
in the virological resistance. New detection and evaluation
platforms, such as deep sequencing or new animal models
will be discussed for their application for this important
issue.
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HBV cccDNA, the template for transcription of all viral
mRNAs, accumulates in the nucleus of infected cells as a
stable episome organized into minichromosomes by histones
and non-histone viral and cellular proteins (Levrero et
al., J. Hepatol 51, 581, 2009). The accumulation and the
maintenance of the cccDNA pool is ensured in infected
hepatocytes by newly synthesized nucleocapsids which
are not enveloped and secreted into the blood, but are
transported into the nucleus. In quiescent cells the cccDNA
is very stable and can persist throughout the life span of
the hepatocytes without affecting its viability. A reduction
of the cccDNA pool in the infected liver can be achieved
either by cell death or through cccDNA dilution during cell
division. Thus, liver cell death and regeneration that occur
in chronically infected livers may be instrumental not only
to eliminate infected cells but also to induce hepatocyte
proliferation which, in turn, may favour cccDNA loss. On
the other hand, very low levels of cccDNA can persist
indeﬁnitely, possibly explaining lifelong immune responses
to HBV despite clinical resolution of HBV infection. As HBV
polymerase inhibitors do not directly affect the cccDNA,
a decrease in cccDNA levels in patients treated with
nucleot(s)ide analogs is supposed to derive from the lack
of sufﬁcient recycling of viral nucleocapsids to the nucleus,
due to the strong inhibition of viral DNA synthesis in the
cytoplasm, and less incoming viruses from the blood. Under
this scenario, cccDNA depletion requires many years of
nucleos(t)ide drug administration and it is expected to lead
to the selection of resistant variants. Only a simultaneous
treatment with antiviral agents acting through different
mechanisms or capable of affecting cccDNA stability will
hopefully lead to the eradicating of the cccDNA from the
liver and achieve clearance of HBV infection.
We have developed a chromatin immuno-precipitation
(ChIP)-based quantitative technique to study the
recruitment in vivo of cellular and viral proteins onto the
HBV minichromosome (Pollicino et al., Gastroenterology
130, 823, 2006). The HBV cccDNA ChIP assay combines a ChIP
step with a sensitive and speciﬁc real-time PCR protocol
for cccDNA quantiﬁcation. Using an anti-acetylated-H3 or
-H4 cccDNA ChIP assay we found that HBV replication
is regulated, both in HBV replicating Huh7 cells and
in the liver of HBV chronically infected patients by
the acetylation status of H3/H4 histones bound to the
viral cccDNA. Moreover, cellular histone acetyltransferases
CBP, p300 and PCAF/GCN5 and the histone deacetylases
HDAC1 and hSirt1 are all recruited in vivo onto the
cccDNA (Levrero et al., J. Hepatol 51, 581, 2009). We
also found that the HBx regulatory protein produced
in HBV replicating cells is recruited onto the cccDNA
minichromosome. The HBx mutant cccDNA is impaired
in its replication, transcribes signiﬁcantly less pgRNA,
displays a severe impairment in p300 recruitment, an
increased recruitment of the histone deacetylases hSirt1
and HDAC1 and hypoacetylation of cccDNA-bound histones.
These results identify a novel epigenetic mechanism (i.e. to
prevent cccDNA deacetylation) by which HBx controls HBV
replication (belloni et al., PNAS USA 106, 19975, 2009). We
also found that in HBV replicating cells alpha-IFN treatment
leads to a rapid and strong decrease in both cccDNA-bound
histone acetylation and pgRNA transcription from cccDNA
that are paralleled by the recruitment of the transcriptional
corepressors HDAC1, hSirt1, YY1 and the Polycomb proten
Ezh2 (Belloni et al., submitted to J Clin Invest).
These observations provide a molecular mechanism for
alpha-IFN repression of HBV transcription. Altogether our
results support the existence of a complex network of
epigenetic events that inﬂuence cccDNA function and HBV
replication.
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Chronic hepatitis B is the leading cause of cirrhosis and
hepatocellular carcinoma in Asia. Antiviral therapy against
hepatitis B virus (HBV) has been shown to reduce the
risk of complications, particularly in patients who have
sustained or maintained response to treatment. However,
long-term antiviral therapy is limited by the emergence of
drug-resistant mutants. Drug resistance results in increase
in viral load, hepatitis ﬂares, histological deterioration and
even liver decompensation. While newer antiviral drugs such
